ALKS - Alkermes plc.

QQQ $ 613.28 $ -11.96 (-1.91 %)

DIA $ 485.45 $ -2.47 (-0.51 %)

SPY $ 681.35 $ -7.41 (-1.08 %)

TLT $ 87.29 $ -0.85 (-0.96 %)

GLD $ 395.38 $ 2.20 (0.56 %)

Previous Close

$ 28.5

Open

$ 29.26

Bid

$ 28.54 x 349

Ask

$ 28.55 x 99

Day's Range

$ 28.48 - $ 29.17

52 Week Range

$ 25.17 - $ 36.45

Volume

1,620,234

Average Volume

Market Cap

4.71B

Beta (5Y Monthly)

$ 0.47

PE Ratio (TTM)

$ 13.95

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	10-28-2025	09-30-2025	10-Q
2	07-29-2025	06-30-2025	10-Q
3	05-01-2025	03-31-2025	10-Q
4	02-12-2025	12-31-2024	10-K
5	10-24-2024	09-30-2024	10-Q
6	07-24-2024	06-30-2024	10-Q
7	05-01-2024	03-31-2024	10-Q
8	02-21-2024	12-31-2023	10-K
9	10-25-2023	09-30-2023	10-Q
10	07-26-2023	06-30-2023	10-Q
11	04-26-2023	03-31-2023	10-Q
12	02-16-2023	12-31-2022	10-K
13	11-02-2022	09-30-2022	10-Q
14	07-27-2022	06-30-2022	10-Q
15	04-27-2022	03-31-2022	10-Q
16	02-16-2022	12-31-2021	10-K
17	10-27-2021	09-30-2021	10-Q
18	07-28-2021	06-30-2021	10-Q
19	04-28-2021	03-31-2021	10-Q
20	02-11-2021	12-31-2020	10-K
21	10-29-2020	09-30-2020	10-Q
22	07-29-2020	06-30-2020	10-Q
23	04-29-2020	03-31-2020	10-Q
24	02-13-2020	12-31-2019	10-K
25	10-23-2019	09-30-2019	10-Q
26	07-25-2019	06-30-2019	10-Q
27	04-25-2019	03-31-2019	10-Q
28	02-15-2019	12-31-2018	10-K
29	10-23-2018	09-30-2018	10-Q
30	07-26-2018	06-30-2018	10-Q
31	04-26-2018	03-31-2018	10-Q
32	02-16-2018	12-31-2017	10-K
33	10-26-2017	09-30-2017	10-Q
34	07-27-2017	06-30-2017	10-Q
35	04-27-2017	03-31-2017	10-Q
36	02-17-2017	12-31-2016	10-K
37	11-02-2016	09-30-2016	10-Q
38	07-28-2016	06-30-2016	10-Q
39	04-28-2016	03-31-2016	10-Q
40	02-25-2016	12-31-2015	10-K

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Alkermes To Acquire Avadel Pharmaceuticals...
12/05/2025 21:03:15

As previously announced, the board of directors of Avadel Pharmaceuticals plc (NASDAQ:AVDL), a public limited company incorpora...

10-health-care-stocks-with-whale-alerts-in-todays-session

10 Health Care Stocks With Whale Alerts In...
11/26/2025 17:35:27

Alkermes Has Increased The Buyout For Avad...
11/19/2025 11:02:52

Truist Securities Maintains Buy on Alkerme...
11/17/2025 13:25:44

Truist Securities analyst Joon Lee maintains Alkermes (NASDAQ:ALKS) with a Buy and raises the price target from $50 to $55.

Avadel Pharmaceuticals' Board Of Directors...
11/17/2025 10:47:42

Lundbeck Proposal Values Avadel at up to $23.00 per Ordinary Share, a Total of Approximately $2.4 billionPursuant to Alkermes T...

lundbecks-higher-buyout-proposal-challenges-alkermes-pending-2-billion-avadel-deal

Lundbeck's Higher Buyout Proposal Challeng...
11/14/2025 16:37:57

Avadel reviews Lundbeck's unsolicited $23 offer while maintaining its agreement with Alkermes as its board evaluates whethe...

Alkermes Says It Is Considering Options Af...
11/14/2025 12:47:54

Avadel Board Says Lundbeck Proposal May Be...
11/14/2025 10:51:53

Avadel Receives Unsolicited Lundbeck Propo...
11/14/2025 10:51:23

12-health-care-stocks-moving-in-thursdays-after-market-session

12 Health Care Stocks Moving In Thursday's...
11/13/2025 21:06:42

Wells Fargo Maintains Overweight on Alkerm...
11/13/2025 15:43:19

Wells Fargo analyst Benjamin Burnett maintains Alkermes (NASDAQ:ALKS) with a Overweight and lowers the price target from $42...

Deutsche Bank Maintains Buy on Alkermes, L...
11/13/2025 11:38:51

Deutsche Bank analyst David Hoang maintains Alkermes (NASDAQ:ALKS) with a Buy and lowers the price target from $55 to $45.

Truist Securities Reiterates Buy on Alkerm...
11/12/2025 18:15:06

Truist Securities analyst Joon Lee reiterates Alkermes (NASDAQ:ALKS) with a Buy and maintains $50 price target.

alkermes-eyes-global-phase-3-trial-after-encouraging-data-from-sleep-disorder-study

Alkermes Eyes Global Phase 3 Trial After E...
11/12/2025 17:46:56

Alkermes' alixorexton met key goals in a phase 2 study for narcolepsy type 2, showing significant improvements in wakefulne...

Alkermes Data From Vibrance-2 Phase 2 Tria...
11/12/2025 12:33:32

Alkermes plc (NASDAQ:ALKS) today announced positive topline results from the Vibrance-2 dose-ranging phase 2 study evaluating a...

this-alkermes-analyst-begins-coverage-on-a-bullish-note-here-are-top-3-initiations-for-tuesday

This Alkermes Analyst Begins Coverage On A...
11/11/2025 13:09:35

Truist Securities Initiates Coverage On Al...
11/11/2025 11:56:32

Truist Securities analyst Joon Lee initiates coverage on Alkermes (NASDAQ:ALKS) with a Buy rating and announces Price Target...

Wells Fargo Maintains Overweight on Alkerm...
10/29/2025 14:16:48

Wells Fargo analyst Benjamin Burnett maintains Alkermes (NASDAQ:ALKS) with a Overweight and lowers the price target from $44...

Needham Maintains Buy on Alkermes, Raises ...
10/29/2025 09:55:29

Needham analyst Ami Fadia maintains Alkermes (NASDAQ:ALKS) with a Buy and raises the price target from $43 to $44.

Earnings Scheduled For October 28, 2025
10/28/2025 11:11:34